Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 523

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 6
Chunk 523
---
back Policy

We have adopted a compensation recovery policy
that is compliant with Nasdaq listing rules as required by the Dodd-Frank Act.

Code of Conduct

We have adopted a Code of Conduct applicable to our directors, officers
and employees, which is available by accessing our public filings at the SEC’s website at www.sec.gov and on our website.
In addition, a copy of our Code of Conduct will be provided without charge upon request from us. We intend to disclose any amendments
to or waivers of certain provisions of our Code of Conduct in a Current Report on Form 8-K. 

Insider Trading Policy

We e have adopted an insider
trading policy and procedures governing the purchase, sale, and/or other dispositions of its securities by directors, officers and employees,
or the Company itself, that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and any listing
standards applicable to the Company.

21

Section 16(a) Beneficial Ownership Reporting
Compliance

Section 16(a) of the Exchange
Act requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our equity securities
to file with the SEC initial reports of ownership and reports of changes in ownership of our shares of common stock and other equity securities.
These executive officers, directors, and greater than 10% beneficial owners are required by SEC regulation to furnish us with copies of
all Section 16(a) forms filed by such reporting persons.

Based solely on our review of
such forms furnished to us and written representations from certain reporting persons, we believe that all filing requirements applicable
to our executive officers, directors and greater than 10% beneficial owners were filed in a timely manner.

ITEM 11. EXECUTIVE COMPENSATION.

No compensation will be paid to our initial shareholders,
officers and directors, or any of their respective affiliates, prior to or in connection with the consummation of our initial business
combination. We pay Drugs Made In America Acquisition LLC a total of $10,000 per month for office space, administrative and support services.
Upon completion of our initial business combination or our liquidation, we will cease making these payments. Our sponsor, its service
providers, officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred or
such agreed-upon compensation as contracted in connection with activities on our behalf such as identifying potential target businesses
and performing due diligence on suitable business combinations